Analysts’ Recent Ratings Changes for Candel Therapeutics (CADL)

Candel Therapeutics (NASDAQ: CADL) has recently received a number of price target changes and ratings updates:

• 8/17/2026 – Candel Therapeutics had its “buy” rating reaffirmed by UBS Group AG.
• 8/16/2026 – Candel Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/14/2026 – Candel Therapeutics had its price target raised by Bank of America Corporation from $9.00 to $12.00. They now have a “neutral” rating on the stock.
• 8/13/2026 – Candel Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $23.00 price target on the stock.
• 8/8/2026 – Candel Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 7/29/2026 – Candel Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $23.00 price target on the stock.
• 7/18/2026 – Candel Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/17/2026 – Candel Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/13/2026 – Candel Therapeutics is now covered by Stifel Nicolaus. They set a “buy” rating and a $22.00 price target on the stock.

Insiders Place Their Bets

In other Candel Therapeutics news, insider Francesca Barone sold 23,447 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $10.06, for a total value of $235,876.82. Following the sale, the insider directly owned 77,362 shares in the company, valued at $778,261.72. This trade represents a 23.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CTO Seshu Tyagarajan sold 7,000 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $12.00, for a total transaction of $84,000.00. Following the transaction, the chief technology officer owned 76,865 shares in the company, valued at approximately $922,380. The trade was a 8.35% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 37,447 shares of company stock valued at $390,017. Insiders own 14.30% of the company’s stock.

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.